COMTAN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, France, Hong Kong SAR China, Ireland, Japan, Lithuania, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Tunisia.

Active ingredients

The drug COMTAN contains one active pharmaceutical ingredient (API):

1	Entacapone UNII 4975G9NM6T - ENTACAPONE
	Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa.
	Read more about Entacapone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COMTAN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BX02	Entacapone	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents
Discover more medicines within N04BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8367J
BR	Câmara de Regulação do Mercado de Medicamentos	511521030072811
CA	Health Products and Food Branch	02243763
EE	Ravimiamet	1200283, 1200294, 1200306
ES	Centro de información online de medicamentos de la AEMPS	98081003
FR	Base de données publique des médicaments	68826958
HK	Department of Health Drug Office	44960
JP	医薬品医療機器総合機構	1169014F1021
LT	Valstybinė vaistų kontrolės tarnyba	1028299, 1028300, 1028301, 1089148, 1089149, 1089150
NL	Z-Index G-Standaard, PRK	52035
NZ	Medicines and Medical Devices Safety Authority	8077
PL	Rejestru Produktów Leczniczych	100087162
SG	Health Sciences Authority	11234P
TN	Direction de la Pharmacie et du Médicament	10283271
US	FDA, National Drug Code	0078-0327, 52427-800
ZA	Health Products Regulatory Authority	32/5.4.1/0684